To assess the cost-effectiveness of three treatments (tiotropium, salmeterol, and no treatment) in patients with moderate chronic obstructive pulmonary disease (COPD). METHODS: A Markov model with a time horizon of one year was developed to evaluate the cost-effectiveness of three treatments including i) tiotropium, ii) salmeterol, and iii) no treatment, in patients with moderate COPD. A hypothetical cohort of 100,000 subjects with moderate COPD with the following characteristics were included in the model: mean age of 65 years, smoking history of 50 pack years, and disease duration of 9.5 years. The efficacy and withdrawal data was taken from published randomized clinical trials of the treatments conducted in patients with moderate COPD. The effectiveness measure was exacerbations avoided per patient per year. Incremental costeffectiveness ratio (ICER) was calculated as additional cost per patient to prevent one exacerbation, compared with the next most expensive option. A payer's perspective was used and only direct costs were included in the study. Sensitivity analyses were conducted to test the robustness of the baseline estimates and the study assumptions. RESULTS: The mean annual costs for no treatment, salmeterol, and tiotropium groups were $392, $1268.7 and $1408.6, respectively. The ICER of tiotropium compared with no treatment group was $1830.46/exacerbation avoided, while the ICER of salmeterol compared with no treatment group was $2454.35/exacerbation avoided. Sensitivity analysis results for study variables were stable over a wide range; however the results were most sensitive to the compliance rates of the drugs. CONCLUSION: In patients with moderate COPD, tiotropium was more cost-effective than salmeterol and no treatment strategy. The study helps demonstrate the cost-effectiveness of new treatment interventions in COPD, which would assist private payers in evaluating the role of costly, yet effective therapies. COSTS-Compared to IPR, total COPD-related costs were similar in FSC and ICS, and reduced by $108 (p < 0.05) in the SAL cohort. However, for total all-cause costs, significant reductions were observed for FSC ($792, P < 0.05) and SAL ($1226, p < 0.05) but not the ICS cohort. CONCLUSION: Compared to the IPR cohort, the FSC cohort was 27% less likely to have a COPD-related event, 10% less likely to have any all-cause event, had similar total COPD-related costs, and had reduced all-cause treatment costs in COPD patients, indicating that FSC is a costeffective initial maintenance therapy compared to IPR.
PRS7

COMPARISON OF EVENTS (HOSPITALIZATIONS AND EMERGENCY DEPARTMENT VISITS) AND COSTS FOR MEDICAID PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY INITIAL MEDICATION REGIMEN
GlaxoSmithKline, Research Triangle Park, NC, USA OBJECTIVES: Limited information is available about the relative benefits of various COPD medication treatments on the outcomes and treatment costs in a Medicaid population. The objective was to compare the effects of initial medication regimens on COPD-related and all-cause events (hospitalizations and/or emergency department visits) and COPD-related and allcause costs for patients with COPD. METHODS: A historical cohort of Texas Medicaid patients aged 40 to 65 years, with COPD-related medical costs (ICD-9-CM = 491, 492, 496), 24 months of continuous enrollment (12 months pre and post), and at least one prescription claim (index) for ipratropium (IPR), inhaled corticosteroids (ICS), salmeterol (SAL) or fluticasone propionate/salmeterol (FSC) between September 1, 2000, and December 31, 2003 were assessed. For analysis of events, Coxproportional hazards regression analyses were conducted controlling for baseline factors and pre-index events. For analyses of costs, a two-part model with logistic regression and generalized linear model (GLM) were used to adjust for baseline characteristics and pre-index utilization and costs. RESULTS: A total of 6793 patients were identified; IPR (n = 4213), ICS (n = 968), SAL (n = 401) and FSC (n = 1211). EVENTS-Compared with IPR, only FSC was associated with a significantly lower risk of any COPD-related event ), and any all-cause events ). COSTS-Compared to IPR, total COPD-related costs were similar in FSC and ICS, and reduced by $108 (p < 0.05) in the SAL cohort. However, for total all-cause costs, significant reductions were observed for FSC ($792, P < 0.05) and SAL ($1226, p < 0.05) but not the ICS cohort. CONCLUSION: Compared to the IPR cohort, the FSC cohort was 27% less likely to have a COPD-related event, 10% less likely to have any all-cause event, had similar total COPD-related costs, and had reduced all-cause treatment costs in COPD patients, indicating that FSC is a costeffective initial maintenance therapy compared to IPR.
PRS8 ASSESSING TREATMENT EFFECTS OF INHALED CORTICOSTEROID ON MEDICAL COSTS AMONG COPD PATIENTS: LONGITUDINAL ANALYSIS OF MANAGED CARE CLAIMS
Akazawa M, Stearns S, Biddle AK University of North Carolina at Chapel Hill, Chapel Hill, NC, USA OBJECTIVES: A longitudinal analysis of managed care claims data was conducted to estimate the treatment effects of inhaled corticosteroids (ICS) on medical costs. METHODS: Patients with Chronic Obstructive Pulmonary Disease (COPD) (ICD-9-CM: 491, 492 or 496), ages 40 years or older, who had 15 months continuous eligibility, and received both ICS and regular inhaled bronchodilators (i.e., anticholinergics or long-acting beta2-agonists) were selected from the claims database. Individual-level data on exposure status and costs were summarized for monthly intervals from up to one-year before the initiation of bronchodilators ("index date") through a two-year follow-up period. A fixed-effects approach that accounted for potential omitted variable biases was used to estimate incremental effects of initiating ICS on medical costs. Interaction teams were included to evaluate the timing of ICS treatment as well as impact of patient age. RESULTS: A total of 10,271 COPD patients were used in the analysis. After adjusting for timevariant factors including use of rescue medications and having conditions of asthma or congestive heart failure, ICS treatment was associated with monthly cost reduction of $43 in COPDrelated medical services and $55 in all-cause medical services. Moreover, a one-month delay of ICS initiation was associated with an additional $2 to $3 per month in medical costs. The largest cost reduction was observed among older COPD patients. CONCLUSION: The findings support evidence that initiation of ICS treatment earlier than the current guideline recommended strategy would be beneficial to prevent exacerbation risks and to reduce overall medical costs from managed care perspective.
PRS9 ESTIMATED COST SAVINGS ASSOCIATED WITH THE USE OF A NEW TASTE-MASKED ORAL CLARITHROMYCIN PREPARATION FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS IN CHILDREN IN GERMANY
Fricke FU 1 , Gabriel A 1 , Lungershausen J 1 , Poulsen Nautrup B 2 1 IMS Health Nuremberg, Germany; 2 Gruenenthal GmbH, Aachen, Germany OBJECTIVES: To evaluate the economic value of a new tastemasked oral clarithromycin preparation (clarithromycin SipTechnology) by estimating the amount of cost savings due to its improved compliance compared to clarithromycin suspension in children with respiratory tract infections (RTI) in Germany.
